Drug Profile
Research programme: RNA interference-based therapeutics - Alnylam/Merck
Alternative Names: RNAis - Alnylam/MerckLatest Information Update: 27 Sep 2007
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Merck & Co
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Spinal cord injuries; Unspecified
Most Recent Events
- 27 Sep 2007 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
- 27 Sep 2007 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 20 Sep 2007 Alnylam Pharmaceuticals and Merck & Co have mutually agreed to terminate their research collaboration